#travoprost

[farmaciamkb]

#duotrav #timolol #travoprost #cuidadodelojo #oftalmologia #gotasoftálmicas ya disponible (en Farmacia MKB 1508 C.A) https://www.instagram.com/p/CQQ2NSZnzg-/?utm_medium=tumblr

[siglerprescriptiondrugcards]

Travoprost

Brand Name: Travatan Z

Common Dosage Forms:

Ophthalmic Solution: 0.004% solution available in 2.5 mL and 5 mL bottles. Travatan Z contains sofZia brand of ionic buffering system

FDA Indications/Dosages:

For the reduction of elevated intraocular pressure in patients with open-angle glaucoma or other intraocular hypertension who are intolerant of other intraocular pressure lowering agents or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering agent: The recommended dose is one drop in the affected eye(s) once daily in the evening. More frequent administration than once daily has been shown to decrease the intraocular lowering effect.

Monitor: IOP

Pharmacology/Pharmacokinetics: Travoprost is a synthetic prostaglandin F analogue which selectively stimulates FP prostanoid receptors. The primary mechanism of action to reduce intraocular pressure is thought to be through increased uveoscleral outflow. Travoprost acts locally without significant systemic action. After absorption, metabolism occurs rapidly with an elimination half-life of approximately 45 minutes.

Drug Interactions: Travatan should not be administered while wearing contact lenses. If another ocular drug is being given to patient, doses of Travatan and the additional drug should be separated by at least 5 minutes.

Contraindications/Precautions: Travatan may permanently change then pigmentation and growth of the eyelashes and increase the pigmentation of the iris and periorbital tissue (eyelid). Use with caution in patients with active intraocular inflammation. Rare cases of macular edema have been reported during use with travoprost ophthalmic solution. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk or macular edema. Pregnancy Category C.

Adverse Effects: The most common adverse effects observed in clinical trials was ocular hyperemia (50%). Ocular adverse effects reported at an incidence of 5-10% included decreased visual acuity, eye discomfort, foreign body sensation, pain, and pruritus. Less common adverse effects include abnormal vision, blepharitis, blurred vision, cataract, conjunctivitis, dry eye, eye disorder, flare, iris discoloration, keratitis, lid margin crusting, photophobia, subconjunctival hemorrhage, and tearing.

Patient Consultation:

Travoprost may cause a brown pigmentation in the iris, eyelashes, and eyelids, and increase the growth of eyelashes. Be advised that treatment of only one eye may make these changes more obvious.

To instill: Lie down or tilt head backward and look up (holding dropper above eye), drop solution inside lower lid, and make sure dropper does not come into contact with eye or finger.

Wait at least 5 minutes before instilling other ophthalmic preparation.

Avoid squinting or closing of eyes tightly after instilling drops.

Do not discontinue therapy without first consulting a physician.

Store in a  cool, dry place away from sunlight and children.

If a dose is missed, instill it as soon as possible. If it is closer to the time of your next dose than the dose you missed, skip the missed dose and return to your dosing schedule.

Contact a physician if the above side effects are severe or persistent.

[amcrasto]

Travoprost

    Travoprost

cas 157283-68-6

[1R-[lα(Z),2β(lE,3R*),3α,5α]]-7-[3,5-Dihydroxy-2-[3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1 -butenyl]cyclopentyl]-5-heptenoic acid, 1 -methylethylester

(+)-16-m-trifluoromethylphenoxy tetranor Prostaglandin F2α isopropyl ester; (+)-Fluprostenol ispopropyl ester

(+)-(5Z,9α,1α,13E,15R)-trihydroxy-16-(3-(trifluoromethyl)phenoxy)-17,18,19,20-tetranor-prosta-5,13-dien-…

View On WordPress